牛牛AI助理已提取核心訊息
Moderna, a biotechnology company specializing in mRNA medicines, has reported a significant decline in net product sales for the year ended December 31, 2023. Net product sales dropped to $6.7 billion, a stark contrast to the $18.4 billion in 2022 and $17.7 billion in 2021. This decrease is attributed to the transition of the COVID-19 vaccine market from pandemic to endemic, resulting in lower demand. Despite this, Moderna's COVID-19 vaccine, Spikevax, remains their only commercial product, with the company having received FDA approval for an updated vaccine targeting the Omicron XBB.1.5 sublineage. Moderna's diverse pipeline includes 42 development candidates across 45 programs, with 40 in clinical studies. The company has also made strides in business development, acquiring OriCiro Genomics and entering strategic collaborations with Life Edit Therapeutics and Generation Bio Co. to expand their capabilities in gene editing and nucleic acid therapeutics. Looking ahead, Moderna plans to optimize the cost structure of their COVID-19 business, focusing on manufacturing cost structure and preparing for the marketing launch of their RSV vaccine candidate, mRNA-1345, in 2024, pending approval.
Moderna, a biotechnology company specializing in mRNA medicines, has reported a significant decline in net product sales for the year ended December 31, 2023. Net product sales dropped to $6.7 billion, a stark contrast to the $18.4 billion in 2022 and $17.7 billion in 2021. This decrease is attributed to the transition of the COVID-19 vaccine market from pandemic to endemic, resulting in lower demand. Despite this, Moderna's COVID-19 vaccine, Spikevax, remains their only commercial product, with the company having received FDA approval for an updated vaccine targeting the Omicron XBB.1.5 sublineage. Moderna's diverse pipeline includes 42 development candidates across 45 programs, with 40 in clinical studies. The company has also made strides in business development, acquiring OriCiro Genomics and entering strategic collaborations with Life Edit Therapeutics and Generation Bio Co. to expand their capabilities in gene editing and nucleic acid therapeutics. Looking ahead, Moderna plans to optimize the cost structure of their COVID-19 business, focusing on manufacturing cost structure and preparing for the marketing launch of their RSV vaccine candidate, mRNA-1345, in 2024, pending approval.
專門從事mRNA藥物的生物技術公司Moderna報告稱，截至2023年12月31日的年度淨產品銷售額大幅下降。產品淨銷售額降至67億美元，與2022年的184億美元和2021年的177億美元形成鮮明對比。這種下降歸因於 COVID-19 疫苗市場從大流行向流行的過渡，導致需求減少。儘管如此，莫德納的 COVID-19 疫苗Spikevax仍然是他們唯一的商用產品，該公司已獲得美國食品藥品管理局批准了針對奧密克龍XBB.1.5亞系的更新疫苗。Moderna的多元化研發渠道包括45個項目的42個開發候選藥物，其中40個正在臨床研究。該公司還在業務發展方面取得了長足的進步，收購了OriCiro Ge...展開全部
專門從事mRNA藥物的生物技術公司Moderna報告稱，截至2023年12月31日的年度淨產品銷售額大幅下降。產品淨銷售額降至67億美元，與2022年的184億美元和2021年的177億美元形成鮮明對比。這種下降歸因於 COVID-19 疫苗市場從大流行向流行的過渡，導致需求減少。儘管如此，莫德納的 COVID-19 疫苗Spikevax仍然是他們唯一的商用產品，該公司已獲得美國食品藥品管理局批准了針對奧密克龍XBB.1.5亞系的更新疫苗。Moderna的多元化研發渠道包括45個項目的42個開發候選藥物，其中40個正在臨床研究。該公司還在業務發展方面取得了長足的進步，收購了OriCiro Genomics，並與Life Edit Therapeutics和Generation Bio Co. 進行了戰略合作，以擴大其在基因編輯和核酸治療方面的能力。展望未來，Moderna計劃優化其 COVID-19 業務的成本結構，重點關注製造成本結構，併爲2024年其呼吸道合胞病毒候選疫苗mRNA-1345的上市做準備，尚待批准。
有用
沒用